CelstemX ™  Plerixafor Injection  24mg


Sayre Therapeutics offers clinicians a plerixafor formulation proven to be an effective hematopoietic stem cell mobilizer

  • Indication: CelstemX ™ is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with Non- Hodgkin’s lymphoma and multiple myeloma
  • Formulation: Plerixafor Injection for subcutaneous administration
  • CelstemX ™ is

o An offering for centres that conduct bone marrow transplantations (BMTs) and can be used by a hematologist and/or medical oncologist at the centres

o Proven to offer better success rate in mobilizing stem cells (used in combination with G-CSF) and improved suitability of patients for transplantation

  • In autologous transplantation cases, patients who failed to yield adequate CD34+ cells (stem cells ) or when patient is considered to be a poor mobilizer, plerixafor along with G-CSF is proven to increase the stem cell harvesting in patients, resulting in more patients proceeding to transplantation.

Approximately 19% of lymphoma and myeloma patients fail to collect the minimum number of cells required for autologous stem cell transplant at first attempt – Pusic, I et al. Biology and Marrow Transplantation.2008, 14: 1045-1056


For more information regarding CelstemX ™, please contact your local Sales Representative or email us at info@sayretherapeutics.com.